Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective pilot study of two routes of faecal microbiota transplant in ulcerative colitis
2015-005753-12Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Aug 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allogeneic fecal microbiota in autoimmune colitis (2 arms), sponsored by University of Birmingham. Primary endpoint: Primary composite outcome. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-005753-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005753-12.